Abstract:Conjugation of the naturally occurring product piplartine (PPT, 1), which is a potent cytotoxic compound and ROS inducer, with a diphenyl sulfonyl-substituted furoxan moiety (namely, 3,4-bis(phenylsulfonyl)-1,2,5-oxadiazole-2-oxide), an important type of NO donor, via an ether linker of different chain lengths is described, characterized and screened for the anticancer potential. The cytotoxicity of the new hybrids was evaluated on a panel of human cancer cell lines (MCF-7, PC3 and OVCAR-3) and two non-cancer human cells (MCF10A and PNT2). In general, the synthesized hybrids were more cytotoxic and selective compared to their furoxan precursors 4-6 and PPT in the above cancer cells. Particularly, PC3 cells are the most sensitive to hybrids 7 and 9 (IC50 values of 240 nM and 50 nM, respectively), while a lower potency was found for the prostate normal cells (IC50 = 17.8 μM and 14.1 μM, respectively), corresponding to selectivity indices of ca. 75 and 280, respectively. NO generation by the PPT-furoxan compounds in PC3 cells was confirmed using the Griess reaction. Furthermore, the cell growth inhibitory effect of 9 was significantly attenuated by the NO scavenger carboxy-PTIO. The intracellular ROS generation by 7 and 9 was also verified, and different assays showed that co-treatment with the antioxidant N-acetyl-l-cysteine (NAC) provided protection against PPT-induced ROS generation. Further mechanistic studies revealed that 7 and 9 had strong cytotoxicity to induce apoptosis in PC3 cells, being mediated, at least in part, by the NO-release and increase in ROS production. Notably, the ability of 9 to induce apoptosis was stronger than that of 7, which may be attributed to higher levels of NO released by 9. Compounds 7 and 9 modulated the expression profiles of critical regulators of cell cycle, such as CDKN1A (p21), c-MYC, and CCND1 (cyclin D1), as well as induced DNA damage. Overall, tethering the furoxan NO-releasing moiety to the cytotoxic natural product PPT had significant impact on the potential anticancer activity and selectivity of the novel hybrid drug candidates, especially 9, as a result of synergistic effects of both furoxan and PPT's ability to release NO, generate ROS, induce DNA damage, and trigger apoptosis.

Novel furoxan NO-donor pemetrexed derivatives: design, synthesis, and preliminary biological evaluation

Synthesis and biological evaluation of novel hybrids of phenylsulfonyl furoxan and phenstatin derivatives as potent anti-tumor agents

Synthesis and Antitumor Evaluation of Novel Hybrids of Phenylsulfonylfuroxan and Estradiol Derivatives

Synthesis and Evaluation of Nitric Oxide-Releasing Derivatives of Farnesylthiosalicylic Acid As Anti-Tumor Agents.

Synthesis and Biological Evaluation of Novel Furozan-Based Nitric Oxide-Releasing Derivatives of Oridonin As Potential Anti-Tumor Agents.

Synthesis and Anti-Lung Cancer Activity of Nitric Oxide-Donating Derivatives of Farnesylthiosalicylic Acid

Furoxan-piplartine hybrids as effective NO donors and ROS inducers in PC3 cancer cells: design, synthesis, and biological evaluation

Synthesis of Novel Furozan-Based Nitric Oxide-Releasing Derivatives of 1-Oxo-oridonin with Anti-Proliferative Activity

Design, Synthesis and Biological Evaluation of Novel Fluorinated Docetaxel Analogues.

Design, Synthesis and Anti-Tumor Evaluation of Novel Steroidal Glycoconjugate with Furoxan Derivatives.

Discovery of novel antitumor nitric oxide-donating β-elemene hybrids through inhibiting the PI3K/Akt pathway.

Novel Nitric Oxide Donors of Phenylsulfonylfuroxan and 3-Benzyl Coumarin Derivatives As Potent Antitumor Agents

Synthesis and Biological Evaluation of Novel Hybrid Matrine Derivatives As Anticancer Agents

Antitumor Platinum(Ii) Complexes Containing Platinum-Based Moieties of Present Platinum Drugs and Furoxan Groups As Nitric Oxide Donors: Synthesis, Dna Interaction, and Cytotoxicity

Synthesis and Evaluation of Furoxan-Based Nitric Oxide-Releasing Derivatives of Tetrahydroisoquinoline As Anticancer and Multidrug Resistance Reversal Agents

Novel Hybrid Compounds Containing Benzofuroxan and Aminothiazole Scaffolds: Synthesis and Evaluation of Their Anticancer Activity

Hybrids of Phenylsulfonylfuroxan and Coumarin As Potent Antitumor Agents.

Design, synthesis and biological evaluation of novel hybrids of quinazoline derivatives and phenylsulfonylfuroxan as potential anti-tumor agents

Synthesis and Anti-cancer Activity of Nitric Oxide Donor-based Matrine Derivatives

Novel Nitric Oxide-Releasing Derivatives of Farnesylthiosalicylic Acid: Synthesis and Evaluation of Antihepatocellular Carcinoma Activity.

No-Releasing Enmein-Type Diterpenoid Derivatives With Selective Antiproliferative Activity And Effects On Apoptosis-Related Proteins